US2010272838A1PendingUtilityA1

Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection

58
Individually held — no corporate assignee on recordPriority: Sep 21, 2007Filed: Sep 22, 2008Published: Oct 28, 2010
Est. expirySep 21, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Patrick T. Prendergast
A61P 31/14A61P 35/00A61P 31/12A61P 31/20A61P 31/16A61P 31/18A61P 11/00A61P 1/16A61K 36/42A61K 31/405A61K 31/704A61K 45/06Y02A50/30
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one thterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one thterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment and/or prophylaxis of a viral infection in a subject, wherein the viral infection is caused by a virus selected from the group consisting of a flavivirus, a retrovirus, influenza virus, hepatitis A, hepatitis B, hepatitis D, hepatitis E, hepatitis F, hepatitis G, hepatitis H, autoimmune hepatitis, Bovine Viral Diarrhoea Virus, Dengue virus 1, Dengue virus 2, Dengue virus 3, Dengue virus 4, and Respiratory Syncytical Virus, the method comprising the steps of:
 providing a therapeutically effective amount of a composition comprising an extract of the fruit of  Siraitia grosvenori  Swingle; and   administering the composition to the subject.   
     
     
         2 . A method as claimed in  claim 1  wherein the fruit is Luo Han Guo. 
     
     
         3 - 5 . (canceled) 
     
     
         6 . The method as claimed in  claim 1  wherein the viral infection is a flavivirus and the flavivirus is hepatitis C virus. 
     
     
         7 . (canceled) 
     
     
         8 . The method as claimed in  claim 1  wherein the viral infection is a retrovirus and the retrovirus is HIV. 
     
     
         9 - 31 . (canceled) 
     
     
         32 . The method as claimed in  claim 1  further comprising the step of:
 administering a therapeutically effective amount of a composition comprising a secondary antiviral compound.   
     
     
         33 . The method as claimed in  claim 1  further comprising the step of:
 administering a therapeutically effective amount of a composition comprising a statin or an analogue, metabolite, derivative, pharmaceutically active salt, precursor or pro-drug thereof.   
     
     
         34 - 36 . (canceled) 
     
     
         37 . The method as claimed in  claim 33  wherein the statin is selected from the group consisting of mevastatin, lovastatin, pravastatin, simvastatin, cerivastatin, fluindostatin, velbstatin, fluvastatin, dalvastatin, dihydrocompactin, compactin, atorvastatin, bervastatin and NK-104, ZD-4522. 
     
     
         38 . (canceled) 
     
     
         39 . The method as claimed in  claim 37  wherein the statin is fluvastatin and the fluvastatin is administered as a sodium salt. 
     
     
         40 - 146 . (canceled) 
     
     
         147 . A method for the treatment and/or prophylaxis of a viral infection in a subject, wherein the viral infection is caused by a virus selected from the group consisting of a flavivirus, a retrovirus, influenza virus, hepatitis A, hepatitis B, hepatitis D, hepatitis E, hepatitis F, hepatitis G, hepatitis H, autoimmune hepatitis, Bovine Viral Diarrhoea Virus, Dengue virus 1, Dengue virus 2, Dengue virus 3, Dengue virus 4, and Respiratory Syncytical Virus, the method comprising the steps of:
 providing a therapeutically effective amount of a composition comprising at least one triterpene glycoside or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof; and   administering the composition to the subject.   
     
     
         148 . The method as claimed in  claim 147  wherein the at least one triterpene glycoside or analogue thereof is a mogroside. 
     
     
         149 . The method as claimed in  claim 148  wherein the mogroside is derived from the fruit of  Siraitia grosvenori  Swingle. 
     
     
         150 . The method as claimed in  claim 148  wherein the mogroside is synthetically formed. 
     
     
         151 . The method as claimed in  claim 147  wherein the viral infection is a flavivirus and the flavivirus is hepatitis C virus. 
     
     
         152 . The method as claimed in  claim 147  wherein the viral infection is a retrovirus and the retrovirus is HIV. 
     
     
         153 . The method as claimed in  claim 147  wherein the at least one triterpene glycoside or analogue thereof is selected from the group consisting of 20-hydroxy-11-oxomogroside IA 1 , 11-oxomogroside IIE, 11-oxomogroside IA 1 , mogroside IIE, mogroside III, mogroside IV, mogroside V, siamenoside I, triterpenoid glycoside V, neogroside, Kaempferol 7-α-ι-rhamnopyranoside, Kaempferol 3,7-α-ι-dirhamnopyranoside, 11-oxomogroside III, 11-Dehydroxymogroside III, 11-oxomogroside IV, mogroside II, mogroside VI, 11-oxo-mogroside and siamcroside-I. 
     
     
         154 . The method as claimed in  claim 152  wherein the at least one triterpene glycoside is mogroside V. 
     
     
         155 . The method as claimed in  claim 151  wherein the at least one triterpene glycoside is mogroside IV. 
     
     
         156 . The method as claimed in  claim 147  wherein the at least one triterpene glycoside is halogenated. 
     
     
         157 . The method as claimed in  claim 147  further comprising the step of:
 administering a therapeutically effective amount of a composition comprising a secondary antiviral compound.   
     
     
         158 . The method as claimed in  claim 147  further comprising the step of:
 administering a therapeutically effective amount of a composition comprising a statin or an analogue, metabolite, derivative, pharmaceutically active salt, precursor or pro-drug thereof.   
     
     
         159 . The method as claimed in  claim 158  wherein the statin is selected from the group consisting of mevastatin, lovastatin, pravastatin, simvastatin, cerivastatin, fluindostatin, velbstatin, fluvastatin, dalvastatin, dihydrocompactin, compactin, atorvastatin, bervastatin and NK-104, ZD-4522. 
     
     
         160 . The method as claimed in  claim 159  wherein the statin is fluvastatin and the fluvastatin is administered as a sodium salt.

Join the waitlist — get patent alerts

Track US2010272838A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.